BridgeBio Strikes U.S. Government Deal to Expand Medicaid Access, Lower Drug Costs
Event summary
- BridgeBio Pharma entered a voluntary agreement with the U.S. government to expand Medicaid access to its medicines and lower costs for Americans.
- Attruby®, BridgeBio’s treatment for transthyretin amyloid cardiomyopathy, will be available via the GENEROUS Model for Medicaid patients.
- The agreement ensures BridgeBio avoids future pricing mandates while continuing its ForgingBridges® copay assistance program.
- BridgeBio has three additional medicines under FDA review, with PDUFA dates in November 2026 and May 2027.
The big picture
BridgeBio’s agreement with the U.S. government highlights the growing emphasis on affordability and access in rare disease treatments. The deal underscores the strategic importance of balancing cost reduction with sustained innovation, particularly in conditions with limited treatment options. With three additional medicines in the FDA review pipeline, BridgeBio’s ability to navigate regulatory and pricing challenges will be critical to its long-term success.
What we're watching
- Regulatory Compliance
- Whether BridgeBio can sustain its current pricing model without future mandates, given the evolving healthcare landscape.
- Market Access
- The pace at which BridgeBio expands Medicaid access and the impact on its commercial strategy.
- Pipeline Progress
- How the FDA review timelines for BBP-418, encaleret, and infigratinib will affect BridgeBio’s growth trajectory.